Annovis Bio presents investor deck on path to NDA for Alzheimer's and Parkinson's

Annovis Bio, Inc.

Presentation on December 11, 2024 outlines development path to NDA for Alzheimer's and Parkinson's.
Deck used during live webcast; full content not available in this filing excerpt.
No specific clinical data, financial figures, or milestone dates disclosed in the provided text.

item 7.01 item 9.01

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-127626

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.